Keywords: alnylam, initiates, ph, trial, aln-rsv01, pharmaceuticals, usa-based

Alnylam initiates Ph I trial of ALN-RSV01

Article | 12 December 2005

Print This

Alnylam Pharmaceuticals, a USA-based RNAi therapeutics company, has initiated a Phase I study in Europe to evaluate the human safety ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in